An observational study in Peripheral Arterial Disease and Peripheral Arterial Disease(PAD), sponsored by Biotronik AG. Recruiting at 16 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG — 1 open to participants now, 2 under way, none of them phase 3. Peripheral Arterial Disease · Biotronik SE & Co. KG.
Among the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, this one is one of 2 that started in 2024, is one of 7 observational ones, and was the 15th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →1 of the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG is open now, in 8 countries.
By country, each count listing its studies:
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 200 is close to the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 111 across the 8 interventional studies, 200 across the 7 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Biotronik AG, one of the names counted as Biotronik SE & Co. KG. Under that name alone:
Biotronik AG is the lead sponsor of 40 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Peripheral Arterial Disease by Biotronik SE & Co. KG, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the standard of care practices, procedural outcomes, and in-hospital complications for endovascular peripheral interventions of femoral, popliteal and infrapopliteal lesions.
This is a prospective, multicenter, all-comers observational study. Primary endpoint was procedural success (defined as a combination of successful primary target lesion crossing, residual stenosis of ≤30% following vessel preparation and before definite treatment) and absence of procedural complications (defined as target vessel perforation or rupture, acute occlusion, and distal embolization).
A total of 200 patients will be enrolled, with approximately 100 subjects in ATK group, and 100 subjects in BTK group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Multiple consecutive single lesions with a healthy segment(s) of ≤ 3cm in-between will be considered one lesion.
Above the knee (ATK) group:
Successful treatment of inflow iliac stenosis to the target lesion. Inflow lesion stenosis can be treated during the same procedure as per local standard of care. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and result in ≤30% residual stenosis and no evidence of embolization or significant complications.
Below the knee (BTK) group:
Exclusion Criteria:
Planned vascular surgery procedure within the next 30 days after the ATK and/or BTK procedure on the target limb.
Note: The inflow vessels can be treated on the day of the procedure.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oscar Peripheral Multifunctional Catheter encompasses three components: (i) Oscar Support Catheter with integrated Lock Grip, (ii) Oscar Dilator and (iii) Oscar PTA Balloon. Single Oscar PTA Balloon is also available separately and can only be used together with the pre-supplied Oscar Support Catheter as indicated in the compatibility chart in the Instructions for Use (IFU).
Oscar Procedural success rate
combination of Oscar technical success and absence of serious procedural complications
Time frame: Index procedure
Rate of (Serious) Adverse Device Effects (S)ADE
(Serious) Adverse Device Effects
Time frame: discharge (30 days)
Rate of distal embolization
Distal embolization
Time frame: Index procedure
Rate of target vessel rupture
Target vessel rupture
Time frame: Index procedure
Rate of target vessel perforation
Target vessel perforation
Time frame: Index procedure
Rate of target vessel acute occlusion
Target vessel acute occlusion
Time frame: Index procedure
Rate of Oscar PTA balloon related flow-limiting dissections
flow-limiting dissections defined as NHLBI grade ≥D
Time frame: Index procedure
Rate of peri-operative death (all-cause of death until discharge)
peri-operative death defined as all-cause of death until discharge
Time frame: discharge (30 days)
Rate of unplanned major amputation
unplanned major amputation
Time frame: discharge (30 days)
Oscar crossing success
angiographic confirmation of successful placement of a guidewire into the distal true lumen with Oscar support catheter used together with the dilator and/ or Oscar PTA balloon, and without any additional crossing/re-entry device.
Time frame: Index procedure
Post-Oscar residual stenosis
Post-Oscar residual stenosis (%)
Time frame: Index procedure
Final treatment residual stenosis (%) on the completion angiogram
Final residual stenosis (%) on the completion angiogram
Time frame: Index procedure
Plan to share: Undecided — Not yet decided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 12 months is below that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.